Genmab CEO expects more legal twists in future
Danish biotech company Genmab is currently awaiting the verdict from an arbitration dispute with partner Johnson & Johnson. CEO at Genmab Jan van de Winkel sees an increased chance of more legal cases in the future, as the company continues to grow.
by ANDREAS LØNSTRUP, translated by daniel pedersen
As Genmab gets bigger on all parameters, so too increases the attention from lawyers and legal departments from competitors across the globe, says CEO of Genmab Jan van de Winkel, as reported by Danish business daily Børsen.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab raises 2022 sales outlook to top USD 1.6bn
For subscribers
